Avesthagen

Executive Summary

Avesthagen is an Indian biotechnology company uniquely positioned at the convergence of food, pharma, and population genetics. Its core asset, The Avestagenome Project®, is a systems biology database built on the genetically homogeneous Zoroastrian Parsi community, enabling the identification of disease biomarkers and the development of predictive, preventive, and personalized healthcare solutions. Founded in 2001 and headquartered in Bangalore, the company operates across diagnostics, consumer healthcare, and therapeutic discovery, with a primary focus on oncology and infectious diseases. By leveraging a platform-based approach, Avesthagen aims to transform healthcare through early detection, targeted therapies, and precision medicine, capitalizing on the genetic insights from a well-defined population. The company's long-standing research and proprietary database provide a competitive advantage in biomarker discovery and drug development. While Avesthagen has not disclosed specific financials or clinical milestones, its strategy of combining population genetics with therapeutic and diagnostic applications positions it for potential breakthroughs in personalized medicine. Key upcoming catalysts include the release of new biomarker validation data from the Avestagenome Project, progress in its oncology pipeline, and potential collaborations with global pharmaceutical partners to advance its infectious disease programs.

Upcoming Catalysts (preview)

• Q3 2026Publication of biomarker data from Avestagenome Project in a peer-reviewed journal70% success
• Q1 2027Regulatory approval or launch of a diagnostic test for a cancer type leveraging Parsi population genetics40% success
• Q4 2026Licensing or partnership agreement for an infectious disease therapeutic candidate30% success